|
GB929401A
(en)
|
1958-12-22 |
1963-06-19 |
Upjohn Co |
Encapsulated emulsions and processes for their preparation
|
|
GB969808A
(en)
|
1962-06-08 |
1964-09-16 |
Boots Pure Drug Co Ltd |
Anthelmintic compositions and compounds
|
|
IT1148784B
(it)
|
1980-04-09 |
1986-12-03 |
Eurand Spa |
Procedimento per la preparazione di microcapsule in un veicolo liquido
|
|
US4794000A
(en)
|
1987-01-08 |
1988-12-27 |
Synthetic Blood Corporation |
Coacervate-based oral delivery system for medically useful compositions
|
|
JP2528706B2
(ja)
|
1988-05-30 |
1996-08-28 |
ゼリア新薬工業株式会社 |
ジヒドロピリジン化合物の製剤組成物
|
|
GB8819110D0
(en)
|
1988-08-11 |
1988-09-14 |
Norsk Hydro As |
Antihypertensive drug & method for production
|
|
US5019400A
(en)
|
1989-05-01 |
1991-05-28 |
Enzytech, Inc. |
Very low temperature casting of controlled release microspheres
|
|
US5013557A
(en)
|
1989-10-03 |
1991-05-07 |
Warner-Lambert Company |
Taste masking compositions comprising spray dried microcapsules containing sucralfate and methods for preparing same
|
|
WO1992018106A1
(fr)
|
1991-04-16 |
1992-10-29 |
Nippon Shinyaku Co., Ltd. |
Procede de production d'une dispersion solide
|
|
TW209174B
(https=)
|
1991-04-19 |
1993-07-11 |
Takeda Pharm Industry Co Ltd |
|
|
GB9206757D0
(en)
|
1992-03-27 |
1992-05-13 |
Ferring Bv |
Novel peptide receptor ligands
|
|
AU4198793A
(en)
|
1992-07-24 |
1994-01-27 |
Takeda Chemical Industries Ltd. |
Microparticle preparation and production thereof
|
|
US5565215A
(en)
|
1993-07-23 |
1996-10-15 |
Massachusettes Institute Of Technology |
Biodegradable injectable particles for imaging
|
|
SE9401109D0
(sv)
|
1994-03-31 |
1994-03-31 |
Leiras Oy |
Opthalmic composition II
|
|
SE9401108D0
(sv)
|
1994-03-31 |
1994-03-31 |
Leiras Oy |
Ophthalmic composition I
|
|
US6074642A
(en)
|
1994-05-02 |
2000-06-13 |
Alexion Pharmaceuticals, Inc. |
Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
|
|
GB9412273D0
(en)
|
1994-06-18 |
1994-08-10 |
Univ Nottingham |
Administration means
|
|
US6007845A
(en)
|
1994-07-22 |
1999-12-28 |
Massachusetts Institute Of Technology |
Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
|
|
ATE251896T1
(de)
|
1994-12-19 |
2003-11-15 |
Daiichi Seiyaku Co |
Granulat-präparate mit kontinuierlicher freisetzung und verfahren zur herstellung
|
|
US6413539B1
(en)
|
1996-10-31 |
2002-07-02 |
Poly-Med, Inc. |
Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
|
|
DE69628276T2
(de)
|
1995-07-26 |
2004-04-08 |
Kyowa Hakko Kogyo Co., Ltd. |
Zubereitung von xanthinderivaten als feste dispersion
|
|
US5628984A
(en)
|
1995-07-31 |
1997-05-13 |
University Of North Carolina At Chapel Hill |
Method of detecting lung disease
|
|
US6319897B1
(en)
|
1996-03-13 |
2001-11-20 |
John D. Lambris |
Peptides which inhibit complement activation
|
|
ES2198579T3
(es)
|
1996-07-01 |
2004-02-01 |
Universiteit Utrecht |
Hidrogeles hidrolizables para liberacion controlada.
|
|
EP0842657A1
(en)
|
1996-11-19 |
1998-05-20 |
OctoPlus B.V. |
Microspheres for controlled release and processes to prepare these microspheres
|
|
US6395302B1
(en)
|
1996-11-19 |
2002-05-28 |
Octoplus B.V. |
Method for the preparation of microspheres which contain colloidal systems
|
|
AU7808198A
(en)
|
1997-06-03 |
1998-12-21 |
Biocryst Pharmaceuticals, Inc. |
Novel compounds useful in the complement, coagulat and kallikrein pathways and method for their preparation
|
|
ES2287971T3
(es)
|
1997-08-11 |
2007-12-16 |
Pfizer Products Inc. |
Dispersiones farmaceuticas solidas con biodisponibilidad incrementada.
|
|
NZ507760A
(en)
|
1998-03-26 |
2002-10-25 |
Japan Tobacco Inc |
Amide derivatives and nociceptin antagonists
|
|
KR100818845B1
(ko)
|
1998-09-09 |
2008-04-01 |
메타베이시스 테라퓨틱스, 인크. |
신규한 프럭토스 1,6-비스포스파타제의 헤테로방향족 억제제
|
|
US6287588B1
(en)
|
1999-04-29 |
2001-09-11 |
Macromed, Inc. |
Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof
|
|
AU6868900A
(en)
|
1999-09-03 |
2001-04-10 |
Ajinomoto Co., Inc. |
Novel processes for preparing oxazepine derivatives
|
|
GB9927011D0
(en)
|
1999-11-16 |
2000-01-12 |
Advanced Phytonics Ltd |
Method for the production of particles
|
|
EP1239844B1
(en)
|
1999-12-20 |
2005-06-08 |
Nicholas J. Kerkhof |
Process for producing nanometer particles by fluid bed spray-drying
|
|
EP1967185A1
(en)
|
1999-12-23 |
2008-09-10 |
Pfizer Products Inc. |
Hydrogel-driven drug dosage form
|
|
CN1402629A
(zh)
|
1999-12-23 |
2003-03-12 |
辉瑞产品公司 |
提供提高的药物浓度的药物组合物
|
|
WO2001074400A1
(en)
|
2000-04-03 |
2001-10-11 |
Santen Pharmaceutical Co., Ltd. |
Transporters and drug delivery system by using the same
|
|
US6589549B2
(en)
|
2000-04-27 |
2003-07-08 |
Macromed, Incorporated |
Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles
|
|
US6495164B1
(en)
|
2000-05-25 |
2002-12-17 |
Alkermes Controlled Therapeutics, Inc. I |
Preparation of injectable suspensions having improved injectability
|
|
CN1507357A
(zh)
|
2000-10-31 |
2004-06-23 |
PRҩƷ����˾ |
提高生物活性分子传递的方法和组合物
|
|
GB0122318D0
(en)
|
2001-09-14 |
2001-11-07 |
Novartis Ag |
Organic compounds
|
|
US7528165B2
(en)
|
2001-12-13 |
2009-05-05 |
National Health Research Institutes |
Indole compounds
|
|
WO2003063831A2
(en)
|
2002-02-01 |
2003-08-07 |
Pfizer Products Inc. |
Immediate release dosage forms containing solid drug dispersions
|
|
ITMI20021527A1
(it)
|
2002-07-11 |
2004-01-12 |
Consiglio Nazionale Ricerche |
Anticorpi anti componente c5 del complemento e loro uso
|
|
WO2004007501A1
(en)
|
2002-07-16 |
2004-01-22 |
Amura Therapeutics Limited |
Biologically active compounds
|
|
US9415102B2
(en)
|
2002-09-06 |
2016-08-16 |
Alexion Pharmaceuticals, Inc. |
High concentration formulations of anti-C5 antibodies
|
|
PT1549333E
(pt)
|
2002-09-20 |
2012-01-03 |
Univ Pennsylvania |
Análogos de compstatina com actividade melhorada
|
|
FR2845382A1
(fr)
|
2002-10-02 |
2004-04-09 |
Sanofi Synthelabo |
Derives d'indazolecarboxamides, leur preparation et leur utilisation en therapeutique
|
|
WO2004045518A2
(en)
|
2002-11-15 |
2004-06-03 |
Bristol-Myers Squibb Company |
Open chain prolyl urea-related modulators of androgen receptor function
|
|
AU2003902946A0
(en)
|
2003-06-12 |
2003-06-26 |
Fujisawa Pharmaceutical Co., Ltd. |
Dpp-iv inhibitor
|
|
US20050009910A1
(en)
|
2003-07-10 |
2005-01-13 |
Allergan, Inc. |
Delivery of an active drug to the posterior part of the eye via subconjunctival or periocular delivery of a prodrug
|
|
KR20060085246A
(ko)
|
2003-09-18 |
2006-07-26 |
마커사이트, 인코포레이티드 |
경공막 전달
|
|
EP1713514B1
(en)
|
2004-01-28 |
2021-11-24 |
Johns Hopkins University |
Drugs and gene carrier particles that rapidly move through mucous barriers
|
|
BRPI0506629A
(pt)
|
2004-02-10 |
2007-05-02 |
Univ Colorado |
inibição do fator b, a via alternativa do sistema complemento e métodos relacionados
|
|
RU2393154C2
(ru)
|
2004-03-24 |
2010-06-27 |
Йерини Аг |
Новые соединения для ингибирования ангиогенеза и их применение
|
|
US7417063B2
(en)
|
2004-04-13 |
2008-08-26 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles useful as serine protease inhibitors
|
|
ES2246694B1
(es)
|
2004-04-29 |
2007-05-01 |
Instituto Cientifico Y Tecnologico De Navarra, S.A. |
Nanoparticulas pegiladas.
|
|
US20050244469A1
(en)
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Extended therapeutic effect ocular implant treatments
|
|
WO2005107708A1
(en)
|
2004-04-30 |
2005-11-17 |
Allergan, Inc. |
Biodegradable intravitreal tyrosine kinase inhibitors implants
|
|
US7771742B2
(en)
|
2004-04-30 |
2010-08-10 |
Allergan, Inc. |
Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
|
|
WO2006012373A2
(en)
|
2004-07-20 |
2006-02-02 |
Critical Therapeutics, Inc. |
Combination therapies of hmgb and complement inhibitors against inflammation
|
|
CA2594694A1
(en)
|
2005-01-28 |
2006-08-03 |
Pfizer Products Inc. |
Drying of drug-containing particles
|
|
WO2006082518A1
(en)
|
2005-02-03 |
2006-08-10 |
Pfizer Products Inc. |
Pharmaceutical compositions with enhanced performance
|
|
US8663639B2
(en)
|
2005-02-09 |
2014-03-04 |
Santen Pharmaceutical Co., Ltd. |
Formulations for treating ocular diseases and conditions
|
|
DK1848431T3
(en)
|
2005-02-09 |
2016-04-18 |
Santen Pharmaceutical Co Ltd |
LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS
|
|
CN102016814B
(zh)
|
2005-06-17 |
2013-10-23 |
北卡罗来纳大学查珀尔希尔分校 |
纳米粒子制备方法、系统及材料
|
|
US20070071756A1
(en)
|
2005-09-26 |
2007-03-29 |
Peyman Gholam A |
Delivery of an agent to ameliorate inflammation
|
|
US8168584B2
(en)
|
2005-10-08 |
2012-05-01 |
Potentia Pharmaceuticals, Inc. |
Methods of treating age-related macular degeneration by compstatin and analogs thereof
|
|
WO2007056561A2
(en)
|
2005-11-09 |
2007-05-18 |
Liquidia Technologies, Inc. |
Medical device, materials, and methods
|
|
CN102977191B
(zh)
|
2005-11-28 |
2016-08-10 |
宾夕法尼亚州大学理事会 |
有效的c3补体抑制素类似物
|
|
CA2633541A1
(en)
|
2005-12-12 |
2007-06-21 |
Genelabs Technologies, Inc. |
N-(6-membered aromatic ring)-amido anti-viral compounds
|
|
EP1962803A1
(en)
|
2005-12-23 |
2008-09-03 |
Alcon, Inc. |
PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
|
|
WO2007081876A2
(en)
|
2006-01-04 |
2007-07-19 |
Liquidia Technologies, Inc. |
Nanostructured surfaces for biomedical/biomaterial applications and processes thereof
|
|
JP5819579B2
(ja)
|
2006-01-13 |
2015-11-24 |
サーモディクス，インコーポレイティド |
薬物送達のためのマトリックスを含む微粒子
|
|
US20090220508A1
(en)
|
2006-03-15 |
2009-09-03 |
Alexion Pharmaceuticals, Inc. |
Treatment Of Paroxysmal Nocturnal Hemoglobinuria Patients By An Inhibitor Of Complement
|
|
ES2563288T3
(es)
|
2006-03-23 |
2016-03-14 |
Santen Pharmaceutical Co., Ltd |
Rapamicina en dosis bajas para el tratamiento de enfermedades relacionadas con la permeabilidad vascular
|
|
US20080166411A1
(en)
|
2006-04-10 |
2008-07-10 |
Pfizer Inc |
Injectable Depot Formulations And Methods For Providing Sustained Release Of Poorly Soluble Drugs Comprising Nanoparticles
|
|
WO2007133808A2
(en)
|
2006-05-15 |
2007-11-22 |
Liquidia Technologies, Inc. |
Nano-particles for cosmetic applications
|
|
EP2061433B1
(en)
|
2006-09-08 |
2011-02-16 |
Johns Hopkins University |
Compositions for enhancing transport through mucus
|
|
US9022970B2
(en)
|
2006-10-16 |
2015-05-05 |
Alcon Research, Ltd. |
Ophthalmic injection device including dosage control device
|
|
JPWO2008047831A1
(ja)
|
2006-10-17 |
2010-02-25 |
協和発酵キリン株式会社 |
Ｊａｋ阻害剤
|
|
WO2008067127A2
(en)
|
2006-11-09 |
2008-06-05 |
Alcon Research, Ltd. |
Water insoluble polymer matrix for drug delivery
|
|
US20100216928A1
(en)
|
2006-11-15 |
2010-08-26 |
The University of North Carolona at Chapel Hill |
Polymer particle composite having high fidelity order, size, and shape particles
|
|
JP5070067B2
(ja)
|
2007-01-15 |
2012-11-07 |
参天製薬株式会社 |
ＩκＢキナーゼβ阻害活性を有する新規インドール誘導体
|
|
HUE026001T2
(en)
|
2007-02-05 |
2016-04-28 |
Apellis Pharmaceuticals Inc |
Compstatin analogues for use in the treatment of the inflammatory condition of the respiratory system
|
|
AU2008339917B2
(en)
|
2007-12-24 |
2013-02-07 |
Tibotec Pharmaceuticals |
Macrocyclic indoles as hepatitis C virus inhibitors
|
|
WO2009091826A2
(en)
|
2008-01-14 |
2009-07-23 |
The Board Of Regents Of The University Of Texas System |
Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)
|
|
WO2009100176A2
(en)
|
2008-02-07 |
2009-08-13 |
Abbott Laboratories |
Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
|
|
US9943401B2
(en)
|
2008-04-04 |
2018-04-17 |
Eugene de Juan, Jr. |
Therapeutic device for pain management and vision
|
|
WO2009132206A1
(en)
|
2008-04-25 |
2009-10-29 |
Liquidia Technologies, Inc. |
Compositions and methods for intracellular delivery and release of cargo
|
|
WO2009132265A2
(en)
|
2008-04-25 |
2009-10-29 |
The University Of North Carolina At Chapel Hill |
Degradable compounds and methods of use thereof, particularly with particle replication in non-wetting templates
|
|
WO2010009087A1
(en)
|
2008-07-15 |
2010-01-21 |
Eyegate Pharmaceuticals, Inc. |
Iontophoretic delivery of a controlled-release formulation in the eye
|
|
PY09026846A
(es)
|
2008-08-05 |
2015-09-01 |
Novartis Ag |
Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
|
|
KR101690643B1
(ko)
|
2008-12-05 |
2016-12-28 |
리퀴디아 테크놀로지스 인코포레이티드 |
패턴 재료 제조 방법
|
|
US8623395B2
(en)
|
2010-01-29 |
2014-01-07 |
Forsight Vision4, Inc. |
Implantable therapeutic device
|
|
AU2010208046B2
(en)
|
2009-01-29 |
2014-10-02 |
Forsight Vision4, Inc. |
Posterior segment drug delivery
|
|
WO2010091187A2
(en)
|
2009-02-04 |
2010-08-12 |
The Brigham And Women's Hospital, Inc. |
Polymeric nanoparticles with enhanced drug-loading and methods of use thereof
|
|
WO2010093662A2
(en)
|
2009-02-10 |
2010-08-19 |
Psivida Us, Inc. |
Ocular trocar assembly
|
|
KR101674904B1
(ko)
|
2009-02-26 |
2016-11-10 |
더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 |
중재형 약물전달 시스템과 그 방법
|
|
GB2469471B
(en)
|
2009-04-14 |
2015-01-14 |
Skype |
Optimising communications
|
|
CA2760839C
(en)
|
2009-05-01 |
2019-02-12 |
The Trustees Of The University Of Pennsylvania |
Modified compstatin with peptide backbone and c-terminal modifications
|
|
US10952965B2
(en)
|
2009-05-15 |
2021-03-23 |
Baxter International Inc. |
Compositions and methods for drug delivery
|
|
WO2010135717A2
(en)
|
2009-05-21 |
2010-11-25 |
Potentia Pharmaceuticals, Inc. |
Complement assays and uses thereof
|
|
EP2437684B1
(en)
|
2009-06-03 |
2022-06-15 |
ForSight Vision5, Inc. |
Anterior segment drug delivery
|
|
JP5656996B2
(ja)
|
2009-07-13 |
2015-01-21 |
ザ ユニバーシティ オブ ノース キャロライナ アット チャペル ヒル |
工学的に作製されたエアロゾル粒子、およびそれに関連した方法
|
|
TWI492769B
(zh)
|
2009-09-23 |
2015-07-21 |
Alcon Res Ltd |
可注射的水性眼用組成物及其使用之方法
|
|
EP2490026A4
(en)
|
2009-10-16 |
2013-08-21 |
Mochida Pharm Co Ltd |
MARKER ASSOCIATED WITH NON ALCOHOLIC STÉATOHÉPATITE
|
|
US20130066283A1
(en)
|
2009-10-23 |
2013-03-14 |
Nexisvision, Inc. |
Corneal Denervation for Treatment of Ocular Pain
|
|
EP2490620A4
(en)
|
2009-10-23 |
2017-03-22 |
Forsight Labs, Llc |
Conformable therapeutic shield for vision and pain
|
|
CA2795311A1
(en)
|
2009-11-05 |
2011-05-12 |
Taligen Therapeutics, Inc. |
Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
|
|
TWI478730B
(zh)
|
2009-12-03 |
2015-04-01 |
Alcon Res Ltd |
眼科乳劑
|
|
EA030141B1
(ru)
|
2009-12-31 |
2018-06-29 |
Хатчисон Медифарма Лимитед |
Определенные триазолопиридины и триазолопиразины, их композиции и способы их применения
|
|
WO2013022801A1
(en)
|
2011-08-05 |
2013-02-14 |
Forsight Vision4, Inc. |
Small molecule delivery with implantable therapeutic device
|
|
WO2011106702A2
(en)
|
2010-02-25 |
2011-09-01 |
The Johns Hopkins University |
Sustained delivery of therapeutic agents to an eye compartment
|
|
WO2011109384A2
(en)
|
2010-03-02 |
2011-09-09 |
Allergan, Inc. |
Biodegradable polymers for lowering intraocular pressure
|
|
AU2011239966B2
(en)
|
2010-04-16 |
2014-05-08 |
Ac Immune S.A. |
Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
|
|
CA2798069C
(en)
|
2010-05-05 |
2016-07-05 |
Howard Allen Ketelson |
Stabilized ophthalmic galactomannan formulations
|
|
US8999312B2
(en)
|
2010-06-02 |
2015-04-07 |
Alcon Research, Ltd. |
Use of PBO-PEO-PBO block copolymers in ophthalmic compositions
|
|
WO2011163394A2
(en)
|
2010-06-22 |
2011-12-29 |
Apellis Pharmaceuticals, Inc. |
Compstatin analogs for treatment of neuropathic pain
|
|
US20130324482A1
(en)
|
2010-07-09 |
2013-12-05 |
Apellis Pharmaceuticals, Inc. |
Compstatin analogs for treatment of rhinosinusitis and nasal polyposis
|
|
AU2011285548B2
(en)
|
2010-08-05 |
2014-02-06 |
Forsight Vision4, Inc. |
Combined drug delivery methods and apparatus
|
|
EP3861969A1
(en)
|
2010-08-05 |
2021-08-11 |
ForSight Vision4, Inc. |
Injector apparatus for drug delivery
|
|
CA2807508A1
(en)
|
2010-08-05 |
2012-02-09 |
Forsight Vision4, Inc. |
Subconjunctival implant for posterior segment drug delivery
|
|
CN103209664A
(zh)
|
2010-08-05 |
2013-07-17 |
弗赛特影像4股份有限公司 |
可植入的治疗装置
|
|
EP2611529B1
(en)
|
2010-09-03 |
2019-01-23 |
Bend Research, Inc. |
Spray-drying method
|
|
US10307372B2
(en)
|
2010-09-10 |
2019-06-04 |
The Johns Hopkins University |
Rapid diffusion of large polymeric nanoparticles in the mammalian brain
|
|
WO2012061703A1
(en)
|
2010-11-05 |
2012-05-10 |
The Johns Hopkins University |
Compositions and methods relating to reduced mucoadhesion
|
|
US20140033800A1
(en)
|
2010-11-11 |
2014-02-06 |
Forsight Vision4, Inc. |
Methods and apparatus to determine diffusion properties of porous structures for drug delivery
|
|
WO2012068549A2
(en)
|
2010-11-19 |
2012-05-24 |
Forsight Vision4, Inc. |
Therapeutic agent formulations for implanted devices
|
|
PT2661433T
(pt)
|
2011-01-04 |
2017-10-24 |
Novartis Ag |
Compostos de indole ou seus análogos úteis para o tratamento da degeneração macular relacionada com a idade (amd)
|
|
WO2012109363A2
(en)
|
2011-02-08 |
2012-08-16 |
The Johns Hopkins University |
Mucus penetrating gene carriers
|
|
US9060938B2
(en)
|
2011-05-10 |
2015-06-23 |
Bend Research, Inc. |
Pharmaceutical compositions of active agents and cationic dextran polymer derivatives
|
|
MX356528B
(es)
|
2011-05-11 |
2018-06-01 |
Apellis Pharmaceuticals Inc |
Analogos de compstatina de celula reactiva, de acción prolongada u objetivos y usos de los mismos.
|
|
JP6198721B2
(ja)
|
2011-05-27 |
2017-09-20 |
アキリオン ファーマシューティカルズ，インコーポレーテッド |
Ｈｃｖ感染症を治療するのに有用な置換されたアリファン、シクロファン、ヘテラファン、ヘテロファン、ヘテロ−ヘテラファンおよびメタロセン
|
|
EP2739144A4
(en)
|
2011-06-20 |
2015-04-01 |
Alzheimer S Inst Of America Inc |
COMPOUNDS AND ITS THERAPEUTIC USE
|
|
EP3524258B1
(en)
|
2011-06-22 |
2025-10-01 |
Apellis Pharmaceuticals, Inc. |
Methods of treating chronic disorders with complement inhibitors
|
|
US20130035392A1
(en)
|
2011-08-01 |
2013-02-07 |
Mcgeer Patrick L |
Selective inhibition of the membrane attack complex of complement and C3 convertase by low molecular weight components of the aurin tricarboxylic acid synthetic complex
|
|
CA2847862C
(en)
|
2011-09-07 |
2021-01-12 |
The Trustees Of The University Of Pennsylvania |
Compstatin analogs with improved pharmacokinetic properties
|
|
JP5989780B2
(ja)
|
2011-09-14 |
2016-09-07 |
フォーサイト・ビジョン５・インコーポレイテッドＦｏｒｓｉｇｈｔ Ｖｉｓｉｏｎ５，Ｉｎｃ． |
眼挿入装置および方法
|
|
PT2755600T
(pt)
|
2011-09-16 |
2021-04-19 |
Forsight Vision4 Inc |
Aparelhos de troca de fluidos
|
|
WO2013082111A2
(en)
|
2011-11-29 |
2013-06-06 |
The University Of North Carolina At Chapel Hill |
Geometrically engineered particles and methods for modulating macrophage or immune responses
|
|
BR112014014262A2
(pt)
|
2011-12-14 |
2017-06-13 |
Univ Johns Hopkins |
nanopartículas; composição farmacêutica; método de administrar um ou mais agentes terapêuticos, profiláticos, e/ou diagnósticos a um paciente em necessidade dos mesmos e método de preparação das partículas.
|
|
EP2804632B1
(en)
|
2012-01-19 |
2019-09-18 |
The Johns Hopkins University |
Nanoparticle formulations with enhanced mucosal penetration
|
|
WO2013116061A1
(en)
|
2012-02-03 |
2013-08-08 |
Forsight Vision4, Inc. |
Insertion and removal methods and apparatus for therapeutic devices
|
|
JP6138904B2
(ja)
|
2012-03-16 |
2017-05-31 |
ザ・ジョンズ・ホプキンス・ユニバーシティー |
活性剤の送達のための非線状マルチブロックコポリマー薬物コンジュゲート
|
|
US8962577B2
(en)
|
2012-03-16 |
2015-02-24 |
The Johns Hopkins University |
Controlled release formulations for the delivery of HIF-1 inhibitors
|
|
US20140107025A1
(en)
|
2012-04-16 |
2014-04-17 |
Jade Therapeutics, Llc |
Ocular drug delivery system
|
|
CN111700879A
(zh)
|
2012-05-03 |
2020-09-25 |
卡拉制药公司 |
显示提高的粘膜转移的药物纳米粒子
|
|
ES3055223T3
(en)
|
2012-05-03 |
2026-02-10 |
Alcon Inc |
Pharmaceutical nanoparticles showing improved mucosal transport
|
|
US9827191B2
(en)
|
2012-05-03 |
2017-11-28 |
The Johns Hopkins University |
Compositions and methods for ophthalmic and/or other applications
|
|
JP6360039B2
(ja)
|
2012-05-03 |
2018-07-18 |
カラ ファーマシューティカルズ インコーポレイテッド |
複数の被覆された粒子を含む組成物、医薬組成物、医薬製剤、及び当該粒子の形成方法
|
|
US9056874B2
(en)
|
2012-05-04 |
2015-06-16 |
Novartis Ag |
Complement pathway modulators and uses thereof
|
|
AU2013256008B2
(en)
|
2012-05-04 |
2016-02-25 |
The Johns Hopkins University |
Lipid-based drug carriers for rapid penetration through mucus linings
|
|
EA027113B1
(ru)
|
2012-05-04 |
2017-06-30 |
Новартис Аг |
Регуляторы пути комплемента и их применение
|
|
BR112014031522A2
(pt)
|
2012-06-18 |
2017-08-01 |
Omeros Corp |
métodos para inibir a ativação de complemento dependente de masp-3, para inibir a ativação de complemento dependente de masp-2 e para fabricar um medicamento
|
|
US9579360B2
(en)
|
2012-06-20 |
2017-02-28 |
The Trustees Of The University Of Pennsylvania |
Methods of treating or preventing periodontitis and diseases associated with periodontitis
|
|
EA201590053A1
(ru)
|
2012-06-20 |
2015-08-31 |
Новартис Аг |
Модуляторы пути системы комплемента и их применение
|
|
MX2014015738A
(es)
|
2012-06-28 |
2015-08-06 |
Novartis Ag |
Derivados de pirrolidina y su uso como moduladores de la senda del complemento.
|
|
ES2644700T3
(es)
|
2012-06-28 |
2017-11-30 |
Novartis Ag |
Derivados de pirrolidina y su uso como moduladores de la ruta del complemento
|
|
EP2867225B1
(en)
|
2012-06-28 |
2017-08-09 |
Novartis AG |
Pyrrolidine derivatives and their use as complement pathway modulators
|
|
WO2014002058A2
(en)
|
2012-06-28 |
2014-01-03 |
Novartis Ag |
Complement pathway modulators and uses thereof
|
|
CN104379579B
(zh)
|
2012-06-28 |
2017-03-08 |
诺华股份有限公司 |
吡咯烷衍生物及其作为补体途径调节剂的用途
|
|
US9815819B2
(en)
|
2012-06-28 |
2017-11-14 |
Novartis Ag |
Complement pathway modulators and uses thereof
|
|
WO2014005150A1
(en)
|
2012-06-29 |
2014-01-03 |
Novartis Ag |
Crystalline forms of l-(2-((lr,3s,5r)-3-( (2 -fluoro-3 - (trifluoromethoxy) phenyl) carbamoyl) - 2 -azabicycl o [3.1.0] hexan- 2 -yl) - 2 -oxoethyl) - 5 -methyl - 1h - pyrazolo [3, 4 -c] pyridine - 3 - carboxami de and salts thereof
|
|
ITMI20121156A1
(it)
|
2012-06-29 |
2013-12-30 |
Consiglio Nazionale Ricerche |
Metodo di elaborazione di immagini di tomografia a coerenza ottica
|
|
WO2014002059A1
(en)
|
2012-06-29 |
2014-01-03 |
Novartis Ag |
CRYSTALLINE FORMS OF 1-(2-((1R,3S,5R)-3-(((R)-1-(3-chloro-2-fluorophenyl)ethyl)carbamoyl)-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-1Hpyrazolo[3,4-c]pyridine-3-carboxamide
|
|
CA2882724A1
(en)
|
2012-07-12 |
2014-01-16 |
Novartis Ag |
Complement pathway modulators and uses thereof
|
|
CA2881322A1
(en)
|
2012-09-10 |
2014-03-13 |
F. Hoffmann-La Roche Ag |
6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
|
|
EP2895146A1
(en)
|
2012-09-17 |
2015-07-22 |
BIND Therapeutics, Inc. |
Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
|
|
KR20150090038A
(ko)
|
2012-09-20 |
2015-08-05 |
아키나, 인크. |
충전재를 함유한 생분해성 미세캡슐
|
|
RU2652063C2
(ru)
|
2012-10-26 |
2018-04-24 |
Форсайт Вижн5, Инк. |
Офтальмологическая система для замедленного высвобождения лекарственного средства в глазу
|
|
WO2014078734A2
(en)
|
2012-11-15 |
2014-05-22 |
Apellis Pharmaceuticals, Inc. |
Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
|
|
MX366404B
(es)
|
2012-11-15 |
2019-07-08 |
Apellis Pharmaceuticals Inc |
Analogos de compstatina de celula reactiva, de acción prolongada u objetivos y composiciones y metodos relacionados.
|
|
US9773428B2
(en)
|
2012-12-11 |
2017-09-26 |
Fluidity Software, Inc. |
Computerized system and method for teaching, learning, and assessing step by step solutions to stem problems
|
|
HK1218300A1
(zh)
|
2013-01-23 |
2017-02-10 |
Musc Foundation For Research Development |
基於天然抗體的靶向結構體及其應用
|
|
WO2014152959A1
(en)
|
2013-03-14 |
2014-09-25 |
Forsight Vision4, Inc. |
Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
|
|
US9475806B2
(en)
|
2013-03-14 |
2016-10-25 |
Novartis Ag |
Complement factor B inhibitors and uses there of
|
|
WO2014152391A1
(en)
|
2013-03-15 |
2014-09-25 |
Apellis Pharmaceuticals, Inc. |
Cell-penetrating compstatin analogs and uses thereof
|
|
CN105246438B
(zh)
|
2013-03-28 |
2018-01-26 |
弗赛特影像4股份有限公司 |
用于输送治疗物质的眼科植入物
|
|
AU2014248460B2
(en)
|
2013-04-01 |
2019-04-11 |
Allergan, Inc. |
Microsphere drug delivery system for sustained intraocular release
|
|
JO3425B1
(ar)
|
2013-07-15 |
2019-10-20 |
Novartis Ag |
مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
|
|
KR20160036568A
(ko)
|
2013-07-18 |
2016-04-04 |
노파르티스 아게 |
보체 인자 d 억제제로서의 아미노메틸-비아릴 유도체 및 그의 용도
|
|
JP2016169161A
(ja)
|
2013-07-19 |
2016-09-23 |
大日本住友製薬株式会社 |
新規イミダゾピリジン化合物
|
|
SI3011345T1
(sl)
|
2013-08-07 |
2017-12-29 |
Alexion Pharmaceuticals, Inc. |
Biomarkerski proteini za atipični hemolitični uremični sindrom (ahus)
|
|
US20150104445A1
(en)
|
2013-10-10 |
2015-04-16 |
Viropharma Holdings Limited |
Methods of inhibiting the alternative pathway of complement immune system activation and compositions used therein
|
|
EP3057514A4
(en)
|
2013-10-15 |
2017-08-02 |
Forsight Vision5, Inc. |
Formulations and methods for increasing or reducing mucus
|
|
CN105849090A
(zh)
|
2013-10-30 |
2016-08-10 |
诺华股份有限公司 |
2-苄基-苯并咪唑补体因子b抑制剂及其用途
|
|
WO2015085234A1
(en)
|
2013-12-06 |
2015-06-11 |
Forsight Vision4, Inc. |
Implantable therapeutic devices
|
|
US20160296627A1
(en)
|
2013-12-06 |
2016-10-13 |
Envisia Therapeutics Inc. |
Intracameral implant for treatment of an ocular condition
|
|
US9732103B2
(en)
|
2014-02-25 |
2017-08-15 |
Achillion Pharmaceuticals, Inc. |
Carbamate, ester, and ketone compounds for treatment of complement mediated disorders
|
|
KR102736869B1
(ko)
|
2014-03-07 |
2024-12-02 |
바이오크리스트파마슈티컬즈,인코포레이티드 |
인간 혈장 칼리크레인 저해제
|
|
NZ631007A
(en)
|
2014-03-07 |
2015-10-30 |
Alexion Pharma Inc |
Anti-c5 antibodies having improved pharmacokinetics
|
|
WO2016088082A1
(en)
|
2014-12-05 |
2016-06-09 |
Novartis Ag |
Amidomethyl-biaryl derivatives complement factor d inhibitors and uses thereof
|
|
WO2017024318A1
(en)
|
2015-08-06 |
2017-02-09 |
Dana-Farber Cancer Institute, Inc. |
Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
|
|
WO2017035405A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Amino compounds for treatment of immune and inflammatory disorders
|
|
WO2017035351A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Amino compounds for treatment of medical disorders
|
|
AR105808A1
(es)
|
2015-08-26 |
2017-11-08 |
Achillion Pharmaceuticals Inc |
Compuestos de amida para el tratamiento de trastornos médicos
|
|
WO2017035357A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Phosphonate compounds for treatment of medical disorders
|
|
WO2017035418A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Disubstituted compounds for treatment of immune and inflammatory disorders
|
|
WO2017035362A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Use of complement pathway inhibitor compounds to mitigate adoptive t-cell therapy associated adverse immune responses
|
|
WO2017035409A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
|
|
WO2017035348A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Alkyne compounds for treatment of medical disorders
|
|
WO2017035352A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Carbamate, ester, and ketone compounds for treatment of medical disorders
|
|
WO2017035411A1
(en)
*
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Ether compounds for treatment of immune and inflammatory disorders
|
|
WO2017035401A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Amide compounds for treatment of immune and inflammatory disorders
|
|
WO2017035361A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Disubstituted compounds for the treatment of medical disorders
|
|
WO2017035413A2
(en)
*
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Carbamate, ester, and ketone compounds for treatment of immune and inflammatory disorders
|
|
WO2017035408A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Compounds for treatment of immune and inflammatory disorders
|
|
US10385097B2
(en)
|
2015-08-26 |
2019-08-20 |
Achillion Pharmaceuticals, Inc. |
Ether compounds for treatment of medical disorders
|
|
AR105809A1
(es)
|
2015-08-26 |
2017-11-08 |
Achillion Pharmaceuticals Inc |
Compuestos para el tratamiento de trastornos médicos
|
|
WO2017035415A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Alkyne compounds for treatment of immune and inflammatory disorders
|
|
AR106018A1
(es)
|
2015-08-26 |
2017-12-06 |
Achillion Pharmaceuticals Inc |
Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
|
|
WO2017035417A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Phosphonate compounds for treatment of immune and inflammatory disorders
|
|
DK4019022T3
(en)
|
2015-10-01 |
2024-02-19 |
Biocryst Pharm Inc |
Human plasma kallikrein inhibitors
|
|
AU2016367261A1
(en)
*
|
2015-12-11 |
2018-07-26 |
Lifesci Pharmaceuticals, Inc. |
Therapeutic inhibitory compounds
|
|
JP7339733B2
(ja)
|
2016-01-14 |
2023-09-06 |
ケモセントリックス，インコーポレイティド |
Ｃ３腎症を処置する方法
|
|
WO2017127761A1
(en)
|
2016-01-20 |
2017-07-27 |
Vitrisa Therapeutics, Inc. |
Compositions and methods for inhibiting factor d
|
|
TWI747873B
(zh)
|
2016-02-01 |
2021-12-01 |
美商百歐克斯製藥公司 |
苯并吡唑化合物及其類似物
|
|
SG11201811491YA
(en)
|
2016-06-27 |
2019-01-30 |
Achillion Pharmaceuticals Inc |
Quinazoline and indole compounds to treat medical disorders
|
|
US20190292155A1
(en)
|
2016-07-15 |
2019-09-26 |
Lifesci Pharmaceuticals, Inc. |
Therapeutic inhibitory compounds
|
|
JOP20170154B1
(ar)
|
2016-08-01 |
2023-03-28 |
Omeros Corp |
تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة
|
|
CN110603252A
(zh)
|
2017-03-01 |
2019-12-20 |
艾其林医药公司 |
用于治疗医学障碍的芳基、杂芳基和杂环药物化合物
|
|
EP3589287B1
(en)
|
2017-03-01 |
2022-09-14 |
Achillion Pharmaceuticals, Inc. |
Macrocyclic compounds for treatment of medical disorders
|
|
WO2018160891A1
(en)
|
2017-03-01 |
2018-09-07 |
Achillion Pharmaceutical, Inc. |
Pharmaceutical compounds for treatment of medical disorders
|
|
EP3661493A4
(en)
|
2017-08-02 |
2021-04-14 |
Achillion Pharmaceuticals, Inc. |
THERAPY PLANS FOR TREATMENT OF PAROXYSMALER NIGHTLY HEMOGLOBINURIA
|
|
BR112020006692A2
(pt)
|
2017-10-04 |
2020-10-06 |
Alexion Pharmaceuticals, Inc. |
dosagem e administração de anticorpos anti-c5 para o tratamento de pacientes com glomerulonefrite membranoproliferativa
|
|
US20190359645A1
(en)
|
2018-05-03 |
2019-11-28 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3'-cyclic dinucleotides comprising carbocyclic nucleotide
|
|
KR20210093855A
(ko)
|
2018-09-25 |
2021-07-28 |
아칠리온 파르마세우티칼스 인코포레이티드 |
보체 인자 d 억제제의 형태체 형태
|
|
WO2020131974A1
(en)
|
2018-12-17 |
2020-06-25 |
Achillion Pharmaceuticals, Inc. |
Targeted dosing for the treatment of complement mediated disorders
|